CSF2 and congenital rubella syndrome: GM-CSF is a major contributor in developmentof cytokine releasesyndrome (CRS), a well-known side effect of CAR-T cell therapy. GM-CSFKO CAR-T cells retained antitumor activity while reducing CRS.